Mirum Pharmaceuticals, Inc (MIRM)

Etorro trading 970x250
Mirum Pharmaceuticals, Inc (MIRM) Logo

About Mirum Pharmaceuticals, Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California. Address: 950 Tower Lane, Foster City, CA, United States, 94404

Mirum Pharmaceuticals, Inc News and around…

Latest news about Mirum Pharmaceuticals, Inc (MIRM) common stock and company :

Moore Kuehn, PLLC Encourages Investors of Mirum Pharmaceuticals, Inc. to Contact Law Firm
30 Nov, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own MIRM please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
22 Nov, 2021 FinancialContent

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
17 Nov, 2021 FinancialContent

Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

Look Under The Hood: IWN Has 14% Upside
16 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $199.48 per unit.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss
15 Nov, 2021 Yahoo! Finance

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 4.91% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
15 Nov, 2021 FinancialContent

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
15 Nov, 2021 FinancialContent

6-Year Natural History Comparison with Mirum’s LIVMARLI Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with ALGS

Earnings Scheduled For November 15, 2021
15 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third ...

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov, 2021 FinancialContent

Biotech stocks declined for the second straight week amid a broader market pullback, along withearnings news from small- and ...

Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
08 Nov, 2021 FinancialContent

Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021

New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
01 Nov, 2021 FinancialContent

New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021

The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
01 Nov, 2021 FinancialContent

The Lancet Publishes Data from the ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome

4 Top Biotech Stocks To Watch In October 2021
01 Oct, 2021 FinancialContent
Expert Ratings For Mirum Pharmaceuticals
30 Sep, 2021 FinancialContent

Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

10 Biggest Price Target Changes For Thursday
30 Sep, 2021 FinancialContent

Jefferies raised Perrigo Company plc (NYSE: PRGO) price target from $45 to $63. Perrigo shares jumped 13.3% to $49.27 in pre-market ...

FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma
29 Sep, 2021 FinancialContent

TheFDA has approvedMirum Pharmaceuticals Inc(NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
29 Sep, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 30.57% to $30.02 during Wednesday's after-market session. Today's trading ...

UPDATE 3-Mirum's oral drug becomes first U.S. approved Alagille syndrome therapy
29 Sep, 2021 Yahoo! Finance

Mirum Pharmaceuticals Inc said on Wednesday its drug became the first U.S. approved therapy for treating itching in patients with a rare liver disorder called Alagille syndrome (ALGS). Mirum priced the drug, to be made available for distribution immediately under brand name Livmarli, at $1,550 per unit.

U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
29 Sep, 2021 FinancialContent

FDA Approves LIVMARLI as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with ALGS

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
22 Sep, 2021 Yahoo! Finance

Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.

Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
21 Sep, 2021 FinancialContent

Mirum Pharmaceuticals Inc(NASDAQ: MIRM) andTakeda Pharmaceutical Company Limited(NYSE: TAK)have entered into ...

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
21 Sep, 2021 FinancialContent

Mirum and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals
20 Sep, 2021 FinancialContent

Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings: Bullish Somewhat ...

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
13 Sep, 2021 FinancialContent

Mirum Submits European MAA for Maralixibat in ALGS Supported by New Positive Results from Natural History Study Comparison

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
13 Sep, 2021 Yahoo! Finance

FOSTER CITY, Calif., September 13, 2021--Mirum Submits European MAA for Maralixibat in ALGS Supported by New Positive Results from Natural History Study Comparison

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Sep, 2021 FinancialContent

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We Did The Math IWN Can Go To $191
08 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $191.17 per unit.

Mirum Pharmaceuticals to Participate in September Investor Conferences
02 Sep, 2021 FinancialContent

Mirum Pharmaceuticals to Participate in September Investor Conferences

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
31 Aug, 2021 FinancialContent

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few ...

Mirum Pharmaceuticals, Inc (MIRM) is a NASDAQ Common Stock listed in , ,

970x250